ReviewCold Spring Harbor perspectives in medicine2015
The Economic Promise of Delayed Aging.
Review in Cold Spring Harbor perspectives in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Connecting fragmented aging research through the European Federation for Aging Research.Nature aging · 2026Article
- Aging is not a disease: an evolutionary and comparative biological reappraisal.Biogerontology · 2026Review
- Rejuvenation of white adipose tissue in a longitudinal heterochronic transplantation model.bioRxiv : the preprint server for biology · 2025Article
- A sex-adjusted 7-biomarker clinical aging clock for translational preventative medicine.Scientific reports · 2025Article
- Genetically supported targets and drug repurposing for brain aging: A systematic study in the UK Biobank.Science advances · 2025Article
- Climate geroscience: the case for 'wisdom-inquiry' science.Biology letters · 2024Article
- Prognostic Factors of Mortality and Functional Outcome for Acute Subdural Hematoma: A Review Article.Asian journal of neurosurgery · 2023Review
- Immunomodulation in age-related disorders and nanotechnology interventions.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- From mutation to mechanism: deciphering the molecular function of genetic variants linked to human ageing.Briefings in functional genomics · 2022Article
- Towards the development of phytoextract based healthy ageing cognitive booster formulation, explored throughThe Nucleus : an international journal of cytology and allied topics · 2022Article
- The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19.The lancet. Healthy longevity · 2021Review
- The quest to slow ageing through drug discovery.Nature reviews. Drug discovery · 2020Review
- Genetics of extreme human longevity to guide drug discovery for healthy ageing.Nature metabolism · 2020Review
- Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives.Journal of translational medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomedicine has made enormous progress in the last half century in treating common diseases. However, we are becoming victims of our own success. Causes of death strongly associated with biological aging, such as heart disease, cancer, Alzheimer's disease, and stroke-cluster within individuals as they grow older. These conditions increase frailty and limit the benefits of continued, disease-specific improvements. Here, we show that a "delayed-aging" scenario, modeled on the biological benefits observed in the most promising animal models, could solve this problem of competing risks. The economic value of delayed aging is estimated to be $7.1 trillion over 50 years. Total government costs, including Social Security, rise substantially with delayed aging--mainly caused by longevity increases--but we show that these can be offset by modest policy changes. Expanded biomedical research to delay aging appears to be a highly efficient way to forestall disease and extend healthy life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.